Genetic determinants of blood pressure regulation

Journal of Hypertension

Volumn 23, Issue 12, 2005, Pages 2127-2143

  Marteau, Jean Brice ^a   Zaiou, Mohamed ^a   Siest, Gérard ^a   Visvikis Siest, Sophie ^a  

^a INSERM   (France)

Author keywords

Blood pressure; Candidate genes; Environment; Hypertension; Polymorphism

Indexed keywords

ADDUCIN; AMILORIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; APOLIPOPROTEIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BINDING PROTEIN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCAGON RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 6; RENIN; SODIUM; SODIUM CHANNEL; SOMATOMEDIN C; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE COURSE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MISSENSE MUTATION; NONHUMAN; NORADRENERGIC SYSTEM; OBESITY; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 27944462277     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000186024.12364.2e     Document Type: Review

References (226)

1. Hall WD. Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Am Heart J 1999; 138:225-230.
2. Ward R. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York Raven Press; 1995. pp. 67-68.
3. Hong Y, de Faire U, Heller DA, McClearn GE, Pedersen N. Genetic and environmental influences on blood pressure in elderly twins. Hypertension 1994; 24:663-670.
4. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997;60:265-271.
5. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension 2000;36:477-483.
6. Rice T, Rankinen T, Province MA, Chagnon YC, Pérusse L, Borecki IB, et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Québec Family Study. Circulation 2000; 102:1956-1963.
7. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, et al. MRC British Genetics of Hypertension Study. Genome-wide mapping of human loci for essential hypertension. Lancet 2003;361:2118-2123.
8. Weizmann Institute of Science. http://www.genecards.org
9. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22:239-247.
10. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003; 10:184-196.
11. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
12. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92:2735-2739.
13. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330:1629-1633.
14. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM. Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997; 30:1331-1337.
15. Hata A, Namikawa C, Sasaki M, Sato K, Nakamura T, Tamura K, Lalouel JM. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest 1994; 93:1285-1287.
16. Kato N, Sugiyama T, Morita H, Kurihara H, Yamori Y, Yazaki Y. Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies. J Hypertens 1999; 17:757-763.
17. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension in ischemic heart disease: a meta-analysis. Atheroscler Thromb Vasc Biol 2003; 23:1269-1275.
18. Caulfield M, Lavender P, Newell-Price J, Farrall M, Kamdar S, Daniel H, et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995; 96:687-692.
19. Rodriguez-Perez JC, Rodriguez-Esparragon FJ, Hernandez-Perera O, Fiuza-Perez MD, Anabitarte-Prieto A, Losada-Cabrera A. Effects of the angiotensinogen gene M235T and A(-6)G variants on blood pressure and other vascular risk factors in a Spanish population. J Hum Hypertens 2000; 14:789-793.
20. Niu T, Chen C, Yang J, Wang B, Wang Z, Schork N, et al. Blood pressure and the T174M and M235T polymorphisms of the angiotensinogen gene. Ann Epidemiol 1999; 9:245-253.
21. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99:1786-1797.
22. Jeunemaitre X. Genetic polymorphisms in the renin-angiotensin system. Therapie 1998; 53:271-277.
23. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994; 94:301-310.
24. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, et al. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 1998; 98:1735-1741.
25. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74:953-965.
26. Ramaraj P, Kessler SP, Colmenares C, Sen GC. Selective restoration of male fertility in mice lacking angiotensin-converting enzymes by sperm-specific expression of the testicular isozyme. J Clin Invest 1998; 102:371-378.
27. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205.
28. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997; 15:1579-1592.
29. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997; 156:255-259.
30. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22: 59-62.
31. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
32. Faure-Delanef L, Baudin B, Beneteau-Burnat B, Beaudoin JC, Giboudeau J, Cohen D. Plasma concentration, kinetic constants, and gene polymorphism of angiotensin I-converting enzyme in centenarians. Clin Cnem 1998; 44:2083-2087.
33. Foy CA, McCormack LJ, Knowler WC, Barrett JH, Catto A, Grant PJ. The angiotensin-I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. J Med Genet 1996; 33:336-337.
34. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996; 27:62-66.
35. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992; 184:9-15.
36. Fornage M, Amos CI, Kardia S, Sing CF, Turner ST, Boerwinkle E. Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation 1998; 97:1773-1779.
37. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer E, et al. Evidence for association and genetic linkage of the angiotensin- converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998; 97:1766-1772.
38. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation 2000; 101:2060-2065.
39. Gu XX, Spaepen M, Guo C, Fagard R, Amery A, Lijnen P, et al. Lack of association between the I/D polymorphism of the angiotensin-converting enzyme gene and essential hypertension in a Belgian population. J Hum Hypertens 1994; 8:683-685.
40. Schmidt S, van Hooft IM, Grobbee DE, Ganten D, Ritz E. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study. J Hypertens 1993; 11:345-348.
41. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1992; 1:72-75.
42. Williams SM, Addy JH, Phillips JA 3rd, Dai M, Kpodonu J, Afful J, et al. Combinations of variations in multiple genes are associated with hypertension. Hypertension 2000; 36:2-6.
43. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89:18A-25A.
44. Pilati M, Cicoira M, Zanolla L, Nicoletti I, Muraglia S, Zardini P. The role of angiotensin-converting enzyme polymorphism in congestive heart failure. Congest Heart Fail 2004; 10:87-93.
45. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410:289-302.
46. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-1609.
47. Zhang X, Erdmann J, Regitz-Zagrosek V, Kurzinger S, Hense HW, Schunkert H. Evaluation of three polymorphisms in the promoter region of the angiotensin II type I receptor gene. J Hypertens 2000; 18:267-272.
48. Dzida G, Sobstyl J, Puzniak A, Golon P, Mosiewicz J, Hanzlik J. Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population. Med Sci Monit 2001; 7:1236-1241.
49. Jiang Z, Zhao W, Yu F, Xu G. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Chin Med J (Engl) 2001; 114:1249-1251.
50. Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvanen AC, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999; 33:844-849.
51. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM, et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 2001; 19:1349-1358.
52. Schmidt S, Beige J, Walla-Friedel M, Michel MC, Sharma AM, Ritz E. A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. J Hypertens 1997; 15:1385-1388.
53. Liyou N, Davis D, James K, Simons L, Friedlander Y, Simons J, et al. The A1166C mutation in the angiotensin II type I receptor and hypertension in the elderly. Clin Exp Pharmacol Physiol 1999; 26:525-526.
54. Takahashi N, Murakami H, Kodama K, Kasagi F, Yamada M, Nishishita T, et al. Association of a polymorphism at the 5′-region of the angiotensin II type 1 receptor with hypertension. Ann Hum Genet 2000; 64:197-205.
55. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fugo A, et al. Effects on blood pressure and exploratory behavior of mice lacking angiotensin II type-2 receptor. Nature 1995; 377:748-750.
56. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27:760-765.
57. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34:1112-1116.
58. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 2003; 42:500-506.
59. Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe M, Chen Y, et al. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res 2003; 26:547-552.
60. Eguchi K, Kario K, Hoshide Y, Hoshide S, Ishikawa J, Morinari M, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17:112-117.
61. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, et al., CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26:979-990.
62. Hasimu B, Nakayama T, Mizutani Y, Izumi Y, Asai S, Soma M, et al. Haplotype analysis of the human renin gene and essential hypertension. Hypertension 2003; 41:308-312.
63. Hasimu B, Nakayama T, Mizutani Y, Izumi Y, Asai S, Soma M, et al. A novel variable number of tandem repeat polymorphism of the renin gene and essential hypertension. Hypertens Res 2003; 26:473-477.
64. Morris BJ, Griffiths LR. Frequency in hypertensives of alleles for a RFLP associated with the renin gene. Biochem Biophys Res Commun 1988; 150:219-224.
65. Naftilan AJ, Williams R, Burt D, Paul M, Pratt RE, Hobart P, et al. A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension. Hypertension 1989; 14:614-618.
66. Jeunemaitre X, Rigat B, Charru A, Houot AM, Soubrier F, Corvol P. Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet 1992; 88:301-306.
67. Lum C, Shesely EG, Potter DL, Beierwaltes WH. Cardiovascular and renal phenotype in mice with one or two renin genes. Hypertension 2004; 43:79-86.
68. Frossard PM, Malloy MJ, Lestringant GG, Kane JP. Haplotypes of the human renin gene associated with essential hypertension and stroke. J Hum Hypertens 2001; 15:49-55.
69. Frossard PM, Lestringant GG, Malloy MJ, Kane JP. Human renin gene BgII dimorphism associated with hypertension in two independent populations. Clin Genet 1999; 56:428-433.
70. Zhu X, Chang YP, Van D, Weder A, Cooper R, Luke A, et al. Associations between hypertension and genes in the renin-angiotensin system. Hypertension 2003; 41:1027-1034.
71. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29:233-237.
72. Takahashi S, Inoue H, Miyake Y. The human gene for renin-binding protein. J Biol Chem 1992; 267:13007-13013.
73. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50:1897-1903.
74. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
75. Knoll A, Schunkert H, Reichwald K, Danser AH, Bauer D, Platzer M, et al. Human renin binding protein: complete genomic sequence and association of an intronic T/C polymorphism with the prorenin level in males. Hum Mol Genet 1997; 6:1527-1534.
76. Schmitz C, Gotthardt M, Hinderlich S, Leheste JR, Gross V, Vorum H, et al. Normal blood pressure and plasma renin activity in mice lacking the renin-binding protein, a cellular renin inhibitor. J Biol Chem 2000; 275:15357-15362.
77. Kurokawa K. Tubuloglomerular feedback: its physiological and pathophysiological significance. Kidney Int 1998; 67:S71-S74.
78. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001; 38:1204-1209.
79. Beeks E, Kessels AG, Kroon AA, Van Der Klauw MM, De Leeuw PW. Genetic predisposition to salt-sensitivity: a systematic review. J Hypertens 2004; 22:1243-1249.
80. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994; 91:3999-4003.
81. Zagato L, Modica R, Florio M, Torielli L, Bihoreau MT, Bianchi G, et al. Genetic mapping of blood pressure quantitative trait loci in Milan hypertensive rats. Hypertension 2000; 36:734-739.
82. Marro ML, Scremin OU, Jordan MC, Huynh L, Porro F, Roos KP, et al. Hypertension in beta-adducin-deficient mice. Hypertension 2000; 36:449-453.
83. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349:1353-1357.
84. Glorioso N, Filigheddu F, Cusi D, Troffa C, Conti M, Natalizio M, et al. Alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 2002; 39:357-362.
85. Clark CJ, Davies E, Anderson NH, Farmer R, Friel EC, Fraser R, et al. Alpha-adducin and angiotensin I-converting enzyme polymorphisms in essential hypertension. Hypertension 2000; 36:990-994.
86. Larson N, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans. Hypertension 2000; 35:1297-1300.
87. Wang JG, Staessen JA, Barlassina C, Fagard R, Kuznetsova T, Struijker-Boudier HA, et al. Association between hypertension and variation in the alpha- and beta-adducin genes in a white population. Kidney Int 2002; 62:2152-2159.
88. Tikhonoff V, Kuznetsova T, Stolarz K, Bianchi G, Casiglia E, Kawecka-Jaszcz K, et al. European Project on Genes in Hypertension Investigators. Blood pressure phenotypes in relation to the beta-adducin C1797T polymorphism in the European Project on Genes in Hypertension (EPOCH). Blood Press Monit 2003; 8:151-154.
89. Tikhonoff V, Kuznetsova T, Stolarz K, Bianchi G, Casiglia E, Kawecka-Jaszcz K, et al. beta-Adducin polymorphisms, blood pressure, and sodium excretion in three European populations. Am J Hypertens 2003; 16:840-846.
90. Bianchi G, Ferrari P, Staessen JA. Adducin polymorphism. Detection and impact on hypertension and related disorders. Hypertension 2005; 45:331-340.
91. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
92. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407-414.
93. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996; 12:248-253.
94. Bonny O, Hummler E. Dysfunction of epithelial sodium transport: from human to mouse. Kidney Int 2000; 57:1313-1318.
95. Iwai N, Baba S, Mannami T, Ogihara T, Ogata J. Association of a sodium channel alpha subunit promoter variant with blood pressure. J Am Soc Nephrol 2002; 13:80-85.
96. Ambrosius WT, Bloem U, Zhou L, Rebhun JF, Snyder PM, Wagner MA, et al. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension 1999; 34:631-637.
97. Sugiyama T, Kato N, Ishinaga Y, Yamori Y, Yazaki Y. Evaluation of selected polymorphisms of the Mendelian hypertensive disease genes in the Japanese population. Hypertens Res 2001; 24:515-521.
98. Wong ZY, Stebbing M, Ellis JA, Lamantia A, Harrap SB. Genetic linkage of beta and gamma subunits of epithelial sodium channel to systolic blood pressure. Lancet 1999; 353:1222-1225.
99. + channel in essential hypertension. Hypertension 1998; 32:129-137.
100. Inoue T, Okauchi Y, Matsuzaki Y, Kuwajima K, Kondo H, Horiuchi N, et al. Identification of a single cytosine base insertion mutation at Arg-597 of the beta subunit of the human epithelial sodium channel in a family with Liddle's disease. Eur J Endocrinol 1998; 138:691-697.
101. Melander O, Orho M, Fagerudd J, Bengtsson K, Groop PH, Mattiasson I, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension 1998; 31:1118-1124.
102. Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinla AK, Markandu ND, et al. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998; 351:1388-1392.
103. Dong YB, Plange-Rhule J, Owusu I, Micah F, Eastwood JB, Carter ND, et al. T594M mutation of the beta-subunit of the epithelial sodium channel in Ghanaian populations from Kumasi and London and a possible association with hypertension. Genet Test 2002; 6:63-65.
104. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, et al. Amiloride, a specific drug for hypertension in Black people with T594M variant? Hypertension 2002; 40:13-17.
105. Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol 2001; 281:C1413-C1421.
106. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, et al. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cell growth. J Clin Invest 1994; 94:824-829.
107. Garcia R, Thibault G, Cantin M, Genest J. Effects of purified atrial natriuretic factor on rat and rabbit vascular strips and vascular beds. Am J Physiol 1984; 247:R34-R39.
108. Johnston CI, Hodsman PG, Kohzuki M, Casley DJ, Fabris B, Phillips PA. Interaction between natriuretic peptide and the renin angiotensin aldosterone system. Am J Med 1989; 87:24S-28S.
109. Samson WK. Atrial natriuretic factor inhibits dehydration and hemorrhage-induced vasopressin release. Neuroendocrinology 1985; 40:277-279.
110. Nakamaru M, Inagami T. Atrial natriuretic factor inhibits norepinephrine release evoked by sympathetic nerve stimulation in isolated perfused rat mesenteric arteries. Eur J Pharmacol 1986; 123:459-461.
111. Lucarelli K, lacoviello M, Dessi-Fulgheri P, Sarzani R, Romito R, Sorrentino S. Natriuretic peptides and essential arterial hypertension. Ital Heart J Suppl 2002; 3:1085-1091.
112. Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics 2000; 3:45-58.
113. John SWM, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267:679-681.
114. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990; 16:301-307.
115. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-48.
116. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein B(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-743.
117. Izawa H, Yamada Y, Okada T, Tanaka M, Hirayama H, Yokota M. Prediction of genetic risk for hypertension. Hypertension 2003; 41:1035-1040.
118. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32:510-513.
119. Snapir A, Heinonen P, Tuomainen TP, Lakka TA, Kauhanen J, Salonen JT, et al. G-protein beta3 subunit C825T polymorphism: no association with risk for hypertension and obesity. J Hypertens 2001; 19:2149-2155.
120. Brand E, Herrmann SM, Nicaud V, Ruidavets JB, Evans A, Arveiler D, et al. The 825 C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Hypertension 1999; 33:1175-1178.
121. Huang X, Ju Z, Song Y, Zhang H, Sun K, Lu H, et al. Lack of association between the G protein beta3 subunit gene and essential hypertension in Chinese: a case-control and a family-based study. J Mol Med 2003; 81:729-735.
122. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber CK, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10:1921-1930.
123. Hansen LH, Abrahamsen N, Hager J, Jelinek L, Kindsvogel W, Froguel P, Nishimura E. The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. Diabetes 1996; 45:725-730.
124. Chambers SM, Morris BJ. Glucagon receptor gene mutation in essential hypertension [Letter]. Nat Genet 1996; 12:122.
125. Brand E, Bankir L, Plouin PF, Soubrier F. Glucagon receptor gene mutation (Gly40Ser) in human essential hypertension: the PEGASE study. Hypertension 1999; 34:15-17.
126. Strazzullo P, Iacone R, Siani A, Barba G, Russo O, Russo P, et al. Altered renal sodium handling and hypertension in men carrying the glucagon receptor gene (Gly40Ser) variant. J Mol Med 2001; 79:574-580.
127. Fujisawa T, Ikegami H, Babaya N, Ogihara T. Gly40Ser mutation of glucagon receptor gene and essential hypertension in Japanese [Letter]. Hypertension 1996; 28:1100.
128. Ambrosch A, Lobmann R, Dierkes J, Konig W, Luley C, Lehnert H. Analysis of the Gly40Ser polymorphism in the glucagon receptor gene in a German non-insulin-dependent diabetes mellitus population. Clin Chem Lab Med 1999; 37:719-721.
129. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29:691-619.
130. Nagy Z, Busjahn A, Bahring S, Faulhaber HD, Gohlke HR, Knoblauch H, et al. Quantitative trait loci for blood pressure exist near the IGF-1, the Liddle syndrome, the angiotensin II-receptor gene and the renin loci in man. J Am Soc Nephrol 1999; 10:1709-1716.
131. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50:637-642.
132. Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002; 359:1036-1037.
133. Schut AF, Janssen JA, Deinum J, Vergeer JM, Hofman A, Lamberts SW, et al. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke 2003; 34:1623-1627.
134. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61:167-173.
135. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta-1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-1305.
136. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, et al. Decreased blood pressure response in mice deficient of the alpha(1b)-adrenergic receptor. Proc Natl Acad Sci USA 1997; 94:11589-11594.
137. Feldman RD. Beta-adrenergic receptor alterations in hypertension: physiological and molecular correlates. Can J Physiol Pharmacol 1987; 65:1666-1672.
138. Naslund T, Silberstein DJ, Merrell WJ, Nadeau JH, Wood AJJ. Low sodium intake corrects abnormality in beta-adrenoceptor mediated vasodilation in patients with hypertension: correlation with beta-receptor function in vivo. Clin Pharamacol Ther 1990; 48:87-95.
139. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. β1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
140. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001; 104:187-190.
141. Shioji K, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, et al. Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study. Hypertens Res 2004; 27:31-37.
142. Karlsson J, Lind L, Hallberg P, Michaelsson K, Kurland L, Kahan T. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004; 27:347-350.
143. 2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
144. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, et al. β2-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36:371-375.
145. Brodde OE, Büscher R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thr164Ile β2-adrenoceptors. Circulation 2001; 103:1048-1050.
146. Busjahn A, Li GH, Faulhaber HD, Rosenthal M, Becker A, Jeschke E, et al. beta-2 adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension 2000; 35:555-560.
147. Reihsaus E, Innis M, MacIntyre N, Liggette SB. Mutations in the gene encoding for the b2-adrenergic receptor in normal and asthmatic subjects. Am J Resp Cell Mol 1993; 8:334-339.
148. Liggett SB. Molecular and genetic basis of beta2-adrenergic receptor function. J Allergy Clin Immunol 1999; 104:542-346.
149. Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJ, et al. Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. Hypertension 1997; 30:773-776.
150. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, et al. beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999; 33:1425-1430.
151. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P. Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int 1998; 53:1455-1460.
152. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, et al. Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000; 101:2877-2882.
153. Xie HG, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, et al. Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clin Pharmacol Ther 2000; 67:670-675.
154. Kato N, Sugiyama T, Morita H, Kurihara H, Sato T, Yamori Y, et al. Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension 2001; 37:286-292.
155. Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, et al. Polymorphisms of the beta2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens 2002; 20:229-235.
156. Tomaszewski M, Brain NJ, Charchar FJ, Wang WY, Lacka B, Padmanabahn S, et al. Essential hypertension and beta2-adrenergic receptor gene: linkage and association analysis. Hypertension 2002; 40:286-291.
157. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995; 333:352-354.
158. Silver K, Mitchell BD, Walston J, Sorkin JD, Stern MP, Roth J, et al. TRP64ARG beta 3-adrenergic receptor and obesity in Mexican Americans. Hum Genet 1997; 101:306-311.
159. Tonolo G, Melis MG, Secchi G, Atzeni MM, Angius MF, Carboni A, et al. Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population. J Hypertens 1999; 17:33-38.
160. Strazzullo P, Iacone R, Siani A, Cappuccio FP, Russo O, Barba G, et al. Relationship of the Trp64Arg polymorphism of the beta3-adrenoceptor gene to central adiposity and high blood pressure: interaction with age. Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 2001; 19:399-406.
161. Fujisawa T, Ikegami H, Yamato E, Hamada Y, Kamide K, Rakugi H, et al. Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: insulin resistance and the adrenergic system. Am J Hypertens 1997; 10:101-105.
162. Tamaki S, Iwai N, Tsujita Y, Nakamura Y, Ohmichi N, Kinoshita M. Variant of the beta3-adrenergic receptor gene and coronary atherosclerosis in Japanese subjects. Int J Cardiol 1999; 69:309-311.
163. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci USA 1988; 85:6964-6967.
164. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86:2863-2867.
165. Ergul A. Hypertension in black patients. An emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 2000; 36:62-67.
166. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one kidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 1996; 14:57-64.
167. D'Uscio LV, Barton M, Shaw S, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension - effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997; 30:905-911.
168. Park JB, Schiffrin EL. ETA antagonist prevents blood pressure elevation and vascular hypertrophy of resistance arteries in aldosterone-infused rats. Hypertension 2000; 37:1444-1449.
169. Anderson NB, Armstead CA. Toward understanding the association of socioeconomic status and health: a new challenge for the biopsychosocial approach. Psychosom Med 1995; 57:213-225.
170. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999; 33:1169-1174.
171. Asai T, Ohkubo T, Katsuya T, Higaki J, Fu Y, Fukuda M, et al. Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension 2001; 38:1321-1324.
172. Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe M, Tabara Y, et al. Association of endothelin-1 gene variant with hypertension. Hypertension 2003; 41:163-167.
173. Sharma P, Hingorani A, Jia H, Hopper R, Brown MJ. Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. J Hypertens 1999; 17:1281-1287.
174. Funalot B, Courbon D, Brousseau T, Poirier O, Berr C, Cambien F, et al. EVA Study. Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study. J Hypertens 2004; 22:739-743.
175. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
176. Nicaud V, Poirier O, Behague I, Herrmann SM, Mallet C, Troesch A, et al. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) study. Am J Hypertens 1999; 12:304-310.
177. Benjafield AV, Katyk K, Morris BJ. Association of EDNRA, but not WNK4 or FKBP1B, polymorphisms with essential hypertension. Clin Genet 2003; 64:433-438.
178. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 102:2061-2071.
179. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nafure 2002; 416:337-340.
180. Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F, Benetos A. Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J Hypertens 1998; 16:31-35.
181. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32:3-8.
182. Shoji M, Tsutaya S, Saito R, Takamatu H, Yasujima M. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 2000; 66:2557-2562.
183. Rankinen T, Rice T, Perusse L, Chagnon YC, Gagnon J, Leon AS, et al. NOS3 Glu298Asp genotype and blood pressure response to endurance training: the HERITAGE family study. Hypertension 2000; 36:885-889.
184. Jachymova M, Horky K, Bultas J, Kozich V, Jindra A, Peleska J, et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 2001; 284:426-430.
185. Nakayama T, Soma M, Takahashi Y, Izumi Y, Kanmatsuse K, Esumi M. Association analysis of CA repeat polymorphism of the endothelial nitric oxide synthase gene with essential hypertension in Japanese. Clin Genet 1997; 51:26-30.
186. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Combined effects of endothelial nitric oxide synthase gene polymorphism (G894T) and insulin resistance status on blood pressure and familial risk of hypertension in young adults: the Bogalusa Heart Study. Am J Hypertens 2001; 14:1046-1052.
187. Kimura T, Yokoyama T, Matsumura Y, Yoshiike N, Date C, Muramatsu M, et al. NOS3 genotype-dependent correlation between blood pressure and physical activity. Hypertension 2003; 41:355-360.
188. Minushkina LO, Zateishchikov DA, Zateishchikova AA, Zotova IV, Kudriashova OY, Nosikov VV, et al. NOS3 gene polymorphism and left ventricular hypertrophy in patients with essential hypertension. Kardiologiia 2002; 42:30-34.
189. Hegele RA, Brunt JH, Connelly PW. Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate. Hypertension 1996; 27:308-312.
190. Frossard PM, Obineche EN, Lestringant GG. Association of an apolipoprotein B gene marker with essential hypertension. Hypertension 1999; 33:1052-1056.
191. Higashimori K, Higaki J, Miki T, Kamitani A, Mikami H, Kumahara Y, et al. Analysis of the apolipoprotein B3′ hypervariable region in patients with essential hypertension. Clin Exp Pharmacol Physiol Suppl 1992; 20:21-23.
192. Espino-Montoro A, Barrios-Artillo M, Lopez-Chozas JM, Cayuela A, Stiefel P, Villar J. Influence of polymorphism (RFLP-sstl) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism. Nutr Metab Cardiovasc Dis 2003; 13:194-201.
193. Sass C, Cheng S, Siest G, Visvikis S. Genetic influences on blood pressure within the Stanislas Cohort. J Hypertens 2004; 22:297-304.
194. Jansen H, Waterworth DM, Nicaud V, Ehnholm C, Talmud PJ. Interaction of the common apolipoprotein C-III (APOC3 -482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS-II). Ann Hum Genet 2001; 65:237-243.
195. Xia Y, Sass C, Shen X, Siest G, Visvikis S. Associations of apolipoprotein E concentration and polymorphism with lipids and apolipoprotein levels in Chinese from Beijing and Shanghai. Clin Chem Lab Med 2000; 38:655-659.
196. Uusitupa M, Sarkkinen E, Kervinen K, Kesaniemi YA. Apolipoprotein E phenotype and blood pressure [Letter]. Lancet 1994; 343:57.
197. Corbo RM, Scacchi R, Mureddu L, Mulas G, Castrechini S, Rivasi AP. Apolipoprotein B, apolipoprotein E, and angiotensin-converting enzyme polymorphisms in 2 Italian populations at different risk for coronary artery disease and comparison of allele frequencies among European populations. Hum Biol 1999; 71:933-945.
198. Kauma H, Savolainen MJ, Rantala AO, Lilja M, Kervinen K, Reunanen A, et al. Apolipoprotein E phenotype determines the effect of alcohol on blood pressure in middle-aged men. Am J Hypertens 1998; 11:1334-1343.
199. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis 2001; 159:367-373.
200. Wu DA, Bu X, Warden CH, Shen DD, Jeng CY, Sheu WH, et al. Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. J Clin Invest 1996; 97:2111-2118.
201. Hunt SC, Province MA, Atwood LD, Sholinsky P, Lalouel JM, Rao DC, et al. No linkage of the lipoprotein lipase locus to hypertension in Caucasians. J Hypertens 1999; 17:39-43.
202. Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, et al. Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis 1998; 140:89-95.
203. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001; 60:293-300.
204. Li JJ, Fang CH, Hui RT. Is hypertension an inflammatory disease? Med Hypotheses 2005; 64:236-240.
205. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403.
206. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA study. Am J Hypertens 2004; 17:568-573.
207. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954-960.
208. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
209. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22:2243-2252.
210. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64:616-622.
211. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787.
212. 2 Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20:657-663.
213. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13:7-17.
214. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J 2004; 4:17-23.
215. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-262.
216. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
217. Vormfelde SV, Burckhardt G, Zirk A, Wojnowski L, Brockmoller J. Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 2003; 4:701-734.
218. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
219. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34:8-14.
220. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17:8-13.
221. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-1723.
222. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10:1064-1068.
223. Balati B, Phung H, Pousset F, Isnard R, Boisvieux A, Carayon A, et al. Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. Fundam Clin Pharmacol 2002; 16:361-368.
224. Nurnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gossl M, et al. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 2003; 74:53-60.
225. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
226. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16:834-839.